
Gilead Sciences, Inc. (GILD) operates as a biopharmaceutical company that discovers, develops, and commercializes medicines for unmet medical needs in the United States, Europe, and internationally.
The company’s third-quarter earnings and revenues surpassed Wall Street estimates by 32.9% and 14.8%, respectively, on strong HIV and oncology businesses.